Citations

Clear

13603 citation(s) found for "_, _".

Expanding the Cutaneous Presentation of Blau Syndrome, Response to Treatment, and Correlation With Genetics
Aghazadeh, Nessa , Mittal, Setu , Orandi, Amir B. , Smith, Wendy M. , Khan, Nila S., Davis, Dawn Marie R. , Davis, Dawn M R , Orandi, Amir B , Aghazadeh Mohandesi, Nessa , Mittal, Setu , Khan, Nila S.

Mayo Clinic

Pediatric Dermatology | July 17, 2025 | Volume: 42 | Issue: 5 | Pages: 956-960

10.1111/pde.15994 | PMID 40667856 Get It

ABSTRACTBackgroundBlau syndrome is a rare, autosomal dominant granulomatous disease caused by mutations in the NOD2/CARD15 gene. While the classic triad of arthritis, dermatitis, and uveitis is well known, the full range of cutaneous manifestations remains underexplored.ObjectiveTo expand the understanding of cutaneous findings in Blau syndrome, correlate these findings with NOD2 variants, and evaluate treatment outcomes across organ systems.MethodsA retrospective review of medical records from January 1999 to January 2024 identified 14 patients with Blau syndrome supported by the presence of NOD2 variants. Clinical data on dermatological features, genetics, and treatment responses were analyzed and categorized into specific and non‐specific cutaneous findings.ResultsOf the 14 patients with Blau syndrome, 85% (12/14) demonstrated skin involvement. Specific findings included lichenoid or granulomatous papules and nodules (50%, 6/12), while non‐specific findings (83%, 10/12) were more diverse, including dermatitis (6/10), chronic urticaria (5/10), ichthyosiform eruptions (4/10), vasospastic disorders (5/10), and oral/genital ulcers (2/10). Skin biopsies in three patients with specific findings revealed non‐caseating granulomas. Genetic analysis identified multiple NOD2 variants, though no clear genotype–phenotype correlation was observed. TNF‐alpha inhibitors demonstrated efficacy in controlling ocular and joint disease.ConclusionBlau syndrome presents with a broader spectrum of cutaneous findings than previously recognized. These findings highlight the importance of dermatological evaluation and a multidisciplinary approach to optimize diagnosis and management.
Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Yadav, Siddhartha , Couch, Fergus J. , Hillman, Sam , Luo, Linlin , Li, Weiyan , Li, Qixin , Hayes, Jennifer Fallas , Xu, Xiaoqing , Couch, Fergus J. , Xu, Xiaoqing , Yadav, Siddhartha , Earla, Jagadeswara Rao

Mayo Clinic

JCO Precision Oncology | July 16, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-24-00814 | PMID 40669020 Get It

PURPOSE Testing for germline BRCA1 and/or BRCA2 mutations (gBRCAm) is recommended for patients with human epidermal growth factor receptor 2–negative (HER2–) breast cancer (BC) to guide treatment selection with poly (ADP-ribose) polymerase inhibitors (PARPis). However, real-world data on germline BRCA1 and/or BRCA2 (gBRCA) testing and PARPi treatment patterns in metastatic BC (mBC) are limited. METHODS Deidentified patient data from adults diagnosed with HER2– mBC between 2014 and 2022 were captured from electronic health records in the US Flatiron Health database. gBRCA testing patterns and prevalence were examined by tumor subtype (hormone receptor–positive [HR+]/triple-negative) and disease stage at diagnosis. Demographic and clinical characteristics were described by receipt of gBRCA testing and PARPi. PARPi treatment patterns were assessed, and real-word overall survival (OS) was estimated in patients with gBRCAm diagnosed with mBC after January 1, 2018. RESULTS Of the 15,006 total patients, 4,654 (31.0%) received a gBRCA test. gBRCA testing rates mostly increased from 2014 to 2022 and were lower in patients with HR+ than triple-negative tumors. Of the patients who underwent gBRCA testing, 337 (7.2%) had gBRCAm. From 2018 to 2022, PARPi was initiated in 94 (45.6%) of 206 patients with gBRCAm. With a median follow-up of 22.8 months across patients with available first-line treatment start dates, real-world OS was numerically longer among 94 patients with gBRCAm who received PARPi (32.3 months [95% CI, 22.7 to 47.4]) than among 99 patients who did not (21.9 months [95% CI, 18.4 to not reached]). CONCLUSION Although gBRCA testing increased over time, testing and PARPi utilization rates remained suboptimal in potentially eligible patients with HER2– mBC. Exploratory analysis showed numerically longer OS in patients who received PARPi. Wider and timelier gBRCA testing is warranted to inform potentially optimal treatment decisions.
Quality of Life Assessment Following Botulinum Toxin Injection in Patients with Adductor Spasmodic Dysphonia Using the 5-Factor Glasgow Benefit Inventory
Cirelli, Michael A. , Marino, Michael J. , Lott, David G. , Bansberg, Stephen F. , Lott, David G , Adler, Charles H.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | July 16, 2025 | Volume: 135 | Issue: 1 | Pages: 12-19

10.1177/00034894251356728 | PMID 40665832 Get It

Objectives/Hypothesis: Botulinum neurotoxin type-A (BoNT-A) injection into the true vocal cords is an effective treatment for restoring vocal functionality in adductor spasmodic dysphonia (AdSD). The Glasgow Benefit Inventory was developed to measure quality of life change following any otolaryngologic intervention and was recently revised to a 5-factor subdomain (GBI-5F) questionnaire to improve clinical utility. The study aim was to utilize the GBI-5F to measure patient-reported quality of life change in AdSD patients following BoNT-A injection. Methods: The GBI-5F questionnaire was administered to patients diagnosed with AdSD who received a BoNT-A vocal cord injection between December 2022 and May 2023. All patients had received multiple prior injections. GBI-5F subdomains and demographics were analyzed to identify areas for patient-reported improvement. Results: Sixty-six patients completed the GBI-5F. There were 52 (78.7%) females and average age was 69.4 years. The median total benefit score was +40.0 (interquartile range [IQR], 20.0). Median subdomain scores were +83.3 (IQR, 50.0) for quality of life, +50.0 (IQR, 50.0) for self-confidence, +33.3 (IQR, 33.3) for social involvement, +16.7 (IQR, 50.0) for support, and 0.0 (IQR, 16.7) for general health. Differences in the individual subdomain scores were statistically significant ( P < .0001). No significant differences were found in the total GBI-5F score or any subdomain according to sex or presence of vocal tremor (all P > .05). A moderately positive correlation was noted between median total score and percent functional improvement (r = 0.46, P < .001). Conclusion: Botulinum injection therapy for AdSD provides overall benefit to patients as measured by the GBI-5F, with particular improvement observed for perceived quality of life, self-confidence, and social involvement. Sex, presence/absence of vocal tremor, and age do not appear to modify benefit, though degree of functional improvement is positively correlated with total score.
Spontaneous Hemo-Mediastinum Following Laparoscopic Appendectomy: A Case Report
Awad, Amir, Theerman, Isaac, McBride, J.F., Awad, Abanoub, McBride, Jeremy F, Beckermann, Jason , Awad, Abanoub A

Mayo Clinic

American Journal of Case Reports | July 15, 2025 | Volume: 26 | Issue: No issue available | Pages: No page available

10.12659/ajcr.949251 | PMID 40717320 Get It

Measurement, Estimation, and Correlates of the GFR before and after Bariatric Surgery
Friedman, Allon N. , Chang, Alex R. , Chuah, Ling Ling, Grangeon-Chapon, Caroline , Lane, Kathleen A. , Li, Yang , Roux, Carel W. le , Lieske, John C. , Morales, Enrique , Chagnac, Avry, Favre, Guillaume A , Grangeon-Chapon, Caroline , Lane, Katie A , Li, Yang , le Roux, Carel W , Lieske, John C , Morales, Enrique , Porrini, Esteban , Chang, Alexander R

Mayo Clinic

Journal of the American Society of Nephrology | July 15, 2025 | Volume: 37 | Issue: 1 | Pages: 110-119

10.1681/asn.0000000797 | PMID 40663401 Get It

Key Points In individuals undergoing bariatric surgery, the magnitude of decline in GFR postbariatric surgery is directly associated with presurgery GFR. Reductions in GFR postsurgery were only weakly correlated with weight loss. In obese individuals, GFR-estimating equations performed best when deindexed and when applied in people with reduced kidney function. Background Important questions remain about how bariatric ( i.e ., weight loss) surgery affects measured GFR (mGFR) and eGFR as well as what factors influence change in mGFR postsurgery. Methods Data were pooled from all seven available studies (dates: 2004–2018) measuring GFR prebariatric and postbariatric surgery using gold standard methods. Change in postsurgery mGFR, factors that could influence change in mGFR, and effects on five GFR-estimating equations were analyzed using standard statistical methods. Results The cohort included 105 individuals from the United States and Europe. Sixty-eight percent were female, 97% were White, the mean age was 50 years (range, 24–70), and the mean body mass index was 46±8 kg/m 2 . The mean presurgery mGFR of 107 ml/min (range, 31–215) fell to 92 ml/min (−14%; 95% confidence interval, −21 to −10) postsurgery, with a strong linear relationship existing between presurgery mGFR and % change in GFR ( r =−0.51; −0.64 to −0.35). Individuals with presurgery mGFR ≥90, 60 to <90, and<60 ml/min had −25 (−32 to −19), 1 (−11 to 13), and 7 (0 to 14) ml/min mean postoperative changes in mGFR. Change in weight was significantly correlated with change in mGFR ( r =0.22; 0.03 to 0.40). After adjusting for sex, changes in mGFR postsurgery were associated with higher presurgical age (−0.6 ml/min per year; −1.1 to −0.2), mGFR (−0.5 ml/min per 1 ml/min; −0.6 to −0.4), and change in systolic BP (−0.3 ml/min per 1 mm Hg; −0.6 to 0.0). All GFR-estimating equations significantly underestimated postsurgical GFR reductions in people with preserved kidney function and had improved bias, precision, and accuracy when deindexed and applied to individuals with mGFR <90 ml/min. Conclusions In individuals with obesity undergoing bariatric surgery, the magnitude of postsurgical decline in mGFR was directly associated with presurgery GFR and weakly correlated with weight loss. In addition, GFR-estimating equations' performance improved when deindexed and used in people with reduced kidney function, with the combined creatinine/cystatin C equations having the best overall performance.
Comparative Efficacy and Safety of Cryoballoon vs Laser Balloon Ablation for Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation
Magdon, Dorota, Mounir, Abdulghani, Erickson, Lynn, Adefisoye, James, Kanani, Jim, Kieu, Andy, Ali, Ali , Ghosoun, Nour, Zilinski, Jodi , Mortada, M. Eyman , Bhatia, Atul , Ali, Mahmoud , Erickson, Lynn , Malik, Abdullah , Jahangir, Arshad , Niazi, Imran Khan

Mayo Clinic

Journal of Patient-Centered Research and Reviews | July 15, 2025 | Volume: 12 | Issue: 3 | Pages: 106-112

10.17294/2330-0698.2126 | PMID 40697633 Get It

Purpose: Atrial fibrillation (AF), the most common arrhythmia in older adults, is often treated with cryoballoon ablation (CBA) or laser balloon ablation (LBA) when refractory to medication. We used real-world patient data to investigate differences in arrhythmia-free survival, procedure and fluoroscopy times, and complications between these techniques. Methods: In this single-center, retrospective study of 178 patients with symptomatic paroxysmal AF referred for first-time pulmonary vein isolation (PVI), 103 underwent CBA, and 75 underwent LBA. Recurrence was defined as any atrial arrhythmia of > 30 seconds’ duration after a three-month blanking period. Complications at 30 days were recorded. Kaplan-Meier analysis was used to estimate arrhythmia-free survival at one year for both groups. Categorical variables were expressed as n (%) and continuous variables as mean ± standard deviation or median (Q1, Q3). Results: Baseline characteristics were similar between groups, with exception to left atrial volume index (CBA 32.2 ± 10.9 ml/m2; LBA 36.0 ± 11.0 ml/m2, p = 0.047). History of stroke was higher in CBA (13.6% vs 2.7%; p = 0.012), as was coronary artery disease (35.0% vs 14.7%, p = 0.002). Median fluoroscopy and procedure times (min) were significantly shorter in LBA (24.2 vs 31.6, p = 0.004; 141.0 vs 210.0, p < 0.0001, respectively). One-year arrhythmia-free survival rates were similar (CBA 79.1% vs LBA 78.7%, p = 0.934), as were total complication rates (21.4% vs 16.0%, p = 0.289), including rates of transient ischemic attack/stroke and vascular complications. Conclusions: In patients with paroxysmal AF undergoing PVI, CBA and LBA were equally efficacious at one year and demonstrated acceptably low complication rates. LBA was associated with reduced procedure time and fluoroscopy exposure.
Quality of Life in Adolescents with Cochlear Implant
Bano, Ruqqia, Noor, Hafiza Shabnum, Islam, Amina, Ikram, Faryal, Islam, Amina

Mayo Clinic

Journal of Health, Wellness, and Community Research | July 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: e450

10.61919/3rd5z674 Get It

Background: Cochlear implantation (CI) is a transformative intervention for adolescents with severe-to-profound sensorineural hearing loss, offering benefits that extend beyond auditory rehabilitation to encompass psychosocial and functional outcomes. Despite growing global evidence, there is limited data on the impact of CIs on quality of life (QoL) in low- and middle-income settings, particularly from the adolescent’s perspective. Objective: To evaluate the quality of life of adolescents with unilateral cochlear implants and to assess the influence of demographic and contextual factors on perceived QoL outcomes in a Pakistani cohort. Methods: In this cross-sectional study, 110 adolescents aged 10–19 years with at least 12 months of unilateral CI use were recruited from four rehabilitation centers in Lahore, Pakistan. Participants completed the Glasgow Benefit Inventory (GBI) and a structured demographic questionnaire. Descriptive statistics and inferential analyses compared GBI scores across gender, implant side, and educational placement, with significance set at p < 0.05. Results: The mean GBI total score was 38.6 (SD 11.4), with significant improvements observed across general, social support, and physical health domains (all p < 0.001). No statistically significant differences were found in QoL outcomes by gender, side of implantation, or school type. Strong associations were observed between general well-being and social support. Conclusion: Unilateral cochlear implantation yields substantial, multidimensional quality-of-life benefits for adolescents, independent of demographic or educational context. Integration of psychosocial support and inclusive practices is essential for maximizing post-implant outcomes.
Standardization of Terminology, Definitions, and Outcome Criteria for Bleeding in Hereditary Hemorrhagic Telangiectasia: International Consensus Report
Al‐Samkari, Hanny , Kasthuri, Raj S. , Mager, Hans‐Jurgen, Zhou, Jenny Y. , Serra, Marcelo M. , Samuelson‐Bannow, Bethany T., Doren, Layla N Van , Piccirillo, Jay F. , Clancy, Marianne S. , Thomas, Sonia , Riera‐Mestre, Antoni , Gossage, James R. , Hermans, Cédric , Hammill, Adrienne M. , Drygalski, Annette von , Olitsky, Scott E., Faughnan, Marie E. , Sewaralthahab, Sarah , Iyer, Vivek N , Al-Samkari, Hanny , Hammill, Adrienne , Kasthuri, Raj S , Thomas, Sonia M , McCrae, Keith R. , Pishko, Allyson M. , Iyer, Vivek , Winship, Ingrid , Mei‐Zahav, Meir

Mayo Clinic

American Journal of Hematology | July 15, 2025 | Volume: 100 | Issue: 10 | Pages: 1813-1827

10.1002/ajh.70011 | PMID 40662351 Get It

ABSTRACT Hereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies. However, the lack of consensus on standardized severity definitions, outcome criteria, and terminology remains a major obstacle to clinical investigation and therapeutic development in HHT. Additionally, with the ongoing repurposing of antiangiogenic agents and emerging development of novel HHT‐specific therapies, comparative clinical trials are expected in the future. Therefore, to end the problematic heterogeneity hindering these efforts, the Global Research and Medical Advisory Board (GRMAB) of the Cure HHT Foundation, an international group of recognized HHT experts, convened a conference of expert HHT clinician‐investigators from within GRMAB as well as invited external experts in HHT and bleeding disorders generally, patients with HHT, and patient advocates to define standard terminology and definitions for outcomes and severity classification for bleeding and anemia in HHT. These criteria and definitions should be adopted by regulators, investigators, and the pharmaceutical industry in the development and performance of interventional clinical trials and cohort studies to allow improved comparability between clinical trials, facilitate communication between clinicians and investigators, improve therapeutic guideline development, and provide a standardized framework for regulatory agencies. Search Strategy and Selection Criteria Evidence for this report was systematically identified and evaluated utilizing two search strategies in Ovid MEDLINE, described in full detail in the Appendix, pp.4–13. The searches were conducted on January 7, 2025. The titles and abstracts of each record were reviewed, and the inclusion criteria were applied to all search results to identify full text articles to be retrieved for further review. All retrieved full texts were then reviewed to reach a final determination if a study met the inclusion criteria. Included references were then compiled into evidence tables, which were then utilized by the International Consensus Report Working Group throughout the development of report recommendations.
Development of a hybrid automated chart checking, data collection, and analysis system
Clouser, Edward , Chen, Quan , Harrington, Daniel P. , Rong, Yi , Buckey, C, Clouser, Edward L, Buckey, Courtney R, Rong, Yi , Clouser, Edward Lee

Mayo Clinic

Journal of Applied Clinical Medical Physics | July 14, 2025 | Volume: 26 | Issue: 7 | Pages: No page available

10.1002/acm2.70161 | PMID 40657668 Get It

Abstract Purpose To describe the creation and clinical deployment of an integrated stand‐alone hybrid automated chart review platform that is comprised of a database, oncology information system (OIS) interfaces, and a user interface (UI). Methods A consensus checklist was developed to homogenize the practices of clinical physics staff and physics residents for all plan types. Critical review of the single checklist's items led to the creation of a new concept, the “plan attribute,” which permits specialization of the final checklist based on the characteristics of a particular plan. Only relevant and applicable tests are automatically populated to form a plan checklist based on plan attributes. Each populated checklist in this hybrid automation platform includes elements of full automation, steps or functions that use automation to augment a human input or effort, as well as steps completed by humans. Logging and categorizing of deficiencies found during the chart check was also implemented. Results Chart check data was analyzed for an over 4‐year time span starting from the clinical deployment of the tool in October 2020. This analysis included a total of 427 073 tests spread among 7882 initial chart checks. The recorded deficiencies at three triage levels showed 7116 minor errors, 679 major errors, and 71 plan rejections. The plan rejection level is the highest chart deficiency, which required the plan to be rejected and sent back for serious remediation and/or new plan generation. Conclusion This report describes the successful development and implementation of a hybrid‐automated chart checking program. The software leverages modern database and software design to improve the per case performance and experience of a multi‐user group. Chart check database permits high‐level review and improvement in all aspects of plan check and user performance.
Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial
Aizer, Ayal A. , Tanguturi, Shyam , Catalano, Paul J. , Shin, Kee‐Young , Ricca, Ivy, Johnson, Marciana, Benham, Grant, Kozono, David , Mak, Raymond H. , Hertan, Lauren , Chipidza, Fallon , Krishnan, Monica, Pashtan, Itai , Peng, Luke , Shiloh, R., Cagney, Daniel , Brown, Paul D. , Wen, Patrick Y. , Haas‐Kogan, Daphne A. , Rahman, Rifaquat , Tanguturi, Shyam K , Shi, Diana , Catalano, Paul J , Shin, Kee-Young , Ricca, Ivy , Kozono, David E , Mak, Raymond H , Chipidza, Fallon , Qian, Jack M , Sands, Jacob M , Brown, Paul D , Wen, Patrick Yung , Haas-Kogan, Daphne , Rahman, Rifaquat , Shi, Diana D. , Sands, Jacob

Mayo Clinic

Journal of Clinical Oncology | July 11, 2025 | Volume: 43 | Issue: 27 | Pages: 2986-2997

10.1200/jco-25-00056 | PMID 40644657 Get It

PURPOSE Stereotactic radiation (SRS/SRT) as opposed to whole-brain radiation (WBRT) represents the standard of care for patients with a limited number of brain metastases given the relatively favorable toxicity profile associated with stereotactic treatment. However, in patients with small cell lung cancer (SCLC), WBRT remains standard because of a lack of prospective data supporting SRS/SRT and concerns related to intracranial progression and neurologic death when WBRT is omitted. We conducted a single-arm, multicenter, phase II trial of SRS/SRT in patients with SCLC and 1-10 brain metastases to assess neurologic death rates relative to historical controls managed with WBRT (ClinicalTrials.gov identifier: NCT03391362 ). METHODS Patients were eligible if they had SCLC or an extrathoracic small cell primary and 1-10 brain metastases. Previous brain-directed radiation including prophylactic cranial irradiation was not permitted. Neurologic death was defined as marked, progressive, radiographic brain progression accompanied by corresponding neurologic symptomatology without systemic disease progression or systemic symptoms of a life-threatening nature. Close imaging-based surveillance of the brain post-SRS/SRT was used. RESULTS Between February 2018 and April 2023, 100 patients were enrolled. The median number of brain metastases was 2 (IQR, 1-4; range, 1-10). The median overall survival was 10.2 months; only 22% of patients required salvage WBRT. In total, 20 neurologic deaths were observed, relative to 64 non-neurologic deaths. The neurologic death rate at 1 year was 11.0% (95% CI, 5.8 to 18.1); the historical rate in patients managed with WBRT was 17.5%. CONCLUSION Our prospective, multi-institutional study demonstrated low rates of neurologic death when SRS/SRT as opposed to WBRT is used in patients with SCLC and 1-10 brain metastases who are surveilled closely post-treatment, supporting the utility of stereotactic approaches in this population.